The revenue growth was primarily driven by HTG's collaborative development services activities with pharmaceutical partners including Qiagen.
HTG Molecular Diagnostics offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.
Analyst Puneet Souda said HTG has a growing funnel of biopharma projects that have the potential to convert to companion diagnostics with regulatory approval.
On the heels of the WINTHER study, the consortium has planned a new trial called MERCURY, and will launch a blood and tissue repository.
Qiagen terminated the first project for an NGS-based clinical trial assay after its pharmaceutical partner's phase II drug trial failed to meet its endpoint.
The revenue increase was primarily driven by collaborative development services activities with partners including Qiagen.
HTG Molecular will provide Firalis with technology and components to support its commercialization of a rheumatoid arthritis theranostic assay.
The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.
The company's revenues were primarily driven by its various collaborations, which include ones with Qiagen and Merck KGaA.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.
In Science this week: in vitro generation of human reproductive cells, and more.